Guselkumab is FDA approved to treat moderate to severe plaque psoriasis in adults. Its use for the treatment of psoriatic arthritis is being explored. Guselkumab is provided as a subcutaneous injection of 100 mg given every eight weeks.
Adverse effects
Because guselkumab lowers the release of immune system signalling molecules, patients may have a higher risk of getting infections from bacteria, viruses, and fungi. For this reason, people with psoriasis being considered for treatment with guselkumab must be screened for tuberculosis infection prior to treatment with guselkumab. The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections. As guselkumab is a new medicine, the long term effects are not fully understood.
Pharmacology
Mechanism of action
Guselkumab targets the IL-23 subunit alpha preventing it from binding to cell receptors that would otherwise be activated by its presence.
Guselkumab was developed by Janssen Global Services, LLC. In November 2016, Janssen submitted a Biologics License Application to the FDA seeking approval of guselkumab. In July 2017 Janssen gained US FDA approval to market guselkumab for treatment of plaque psoriasis. In April 2018, Guselkumab was approved in Japan for the treatment psoriatic arthritis. In July 2020, the FDA approved as the first IL-23 inhibitor to treat active psoriatic arthritis in the USA. Guselkumab is manufactured by Janssen Sciences Ireland UC in Cork, Ireland.
Cost
The list price of each 100 mg dose is about $10,000.
Research and development
During development, guselkumab was referred to as CNTO-1959. Guselkumab has undergone phase 3 clinical trials comparing it with adalimumab and ustekinumab. The safety and efficacy of guselkumab was compared to a placebo and to adalimumab in the "VOYAGE 1" and "VOYAGE 2" phase 3 clinical trials. Preliminary results indicated that a significantly higher proportion of patients taking guselkumab had better skin clearance compared to those taking the other treatments. At week 16, 73.3% of patients taking guselkumab achieved a PASI 90, vs 49.7% of those taking adalimumab; additionally, 91.2% of patients taking guselkumab achieved a PASI 75, vs 73.1% of those taking adalimumab. The phase 3 clinical trial "NAVIGATE" included only patients who had poor responses to treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab.
